Bicara Therapeutics Inc. Common Stock BCAX
Analyst Ratings
- Consensus
- Moderate Buy — 8 Buy · 3 Hold · 0 Sell (11 analysts)
- Avg. Price Target
- $32.64 (+234.4% upside)
Key Stats
- Today's Range
- $8.90 – $17.57
- 50-Day Range
- $8.90 – $26.95
- 52-Week Range
- $8.90 – $30.99
- Volume
- 15.42 million shs
- Average Volume
- 1.30 million shs
- Market Cap
- $1.16 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 1.00%
- Days to Cover
- 1.76
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Related Stocks
Compare head-to-head: BCAX vs LLY·BCAX vs JNJ·BCAX vs ABBV·BCAX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.